Novartis, Roche tactics include ops job cuts; HHS blackballs Hermelin, formerly of K-V;

> Novartis has embarked on an "efficiency drive" in which it will optimize its manufacturing network via cross-division centers of excellence; goal: 80-percent utilization at strategic sites. Novartis release

> Roche wants to improve global capacity utilization, too, and its "operational excellence program" involves a reorganization of the manufacturing network to the tune of 1,350 position cuts via job eliminations and the selling of plants. Roche release | Article

> HHS will exclude Marc Hermelin, former chairman of the K-V Pharmaceutical board, from participation in federal health care programs due to his felony guilty plea for failing to report manufacturing problems to the FDA; Hermelin has resigned. K-V release | Article

> Cleanroom garments have seen improvements in operator comfort and in the promotion of correct donning techniques. Article

> The European Trade Commission has published the final text of the Anti-Counterfeiting Trade Agreement. Document (PDF)

> Lee County, Florida is considering spending $5 million to attract an unnamed international pharmaceutical company interested in building a headquarters and manufacturing plant. Article

> Vaccines delivered as nasal drops may hold the key to cold chain headaches. Article

> The FDA and the Philippine Pharmacists Association have teamed to warn people about counterfeit drug proliferation. Article

Suggested Articles

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

A warning letter says Chinese API maker Yibin Lihao Bio-technical was found lying to the FDA about manufacturing unapproved heparin.

It took four tries over four years, but Perrigo has finally gotten FDA approval of its generic of Teva’s tricky-to-make ProAir HFA asthma inhaler.